Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Recurrence 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Hairy Cell 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

pembrolizumab 20Bevacizumab 14Carboplatin 12Standard of Care 10Nivolumab 9Cyclophosphamide 9Cetuximab 8Pemetrexed 7Exercise 7Doxorubicin 7durvalumab 6atezolizumab 6Temozolomide 6Radiotherapy 6Prednisone 6Paclitaxel 6Cisplatin 6Blood Specimen Collection 6abemaciclib 5Fluorouracil 5130-nm albumin-bound paclitaxel 5olaparib 4dostarlimab 4Rituximab 4Leucovorin 4Gemcitabine 4Fulvestrant 4Docetaxel 4Dexamethasone 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × polatuzumab vedotin × 30 days × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡